1 month Cullinan Therapeutics (NASDAQ:CGEM) Receives New Coverage from Analysts at UBS GroupMarketBeat
UBS Group assumed coverage on shares of Cullinan Therapeutics in a research report on Thursday. They issued a “buy” rating and a $30.00 price objective for the company.
X